16% 1st-qtr 2006 sales rise for Schering AG

23 April 2006

In first-quarter 2006, German drugmaker Schering AG achieved net sales of 1.41 billion euros ($1.73 billion), up 16% on the like period of the previous year.

The firm's healthy set of preliminary revenue figures were mainly driven by the multiple sclerosis drug Betaferon/Betaseron (interferon beta-1b), which rose 23% to gross 232.0 million euros, and its contraceptive Yasmin (drospirenone/ethinyl estradiol), which leapt 34% to 180.0 million euros.

The Berlin-headquartered firm says that, once its figures are audited, it anticipates an operating profit for the period of 240.0 million euros, up 4%, noting that, without adjusting for one-time effects relating to divestitures and takeover offers, the operating profit would have amounted to 280.0 million euros, a 22% rise. It says it expects to see profits up 21% to 174.0 million euros, which corresponds to a 21% increase in earnings per share of 0.92 euro.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.